Curtis Harris, MD
Family Medicine · Ada, OKNPI 1235116013
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,125 of the $124,825 with a category attached, or 93.0%. AstraZeneca accounts for 99.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $91,314 and has fallen 99.9% since, to $97 in 2025. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $721.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$124K
- Novo Nordisk$126
- Xeris Pharmaceuticals, Inc.$97
- Sanofi-aventis U.S. LLC$49
- Lilly USA, LLC$39
- Sequel Med Tech, LLC$21
- plus $96 from 6 others
What the payments were for
- Speaking & faculty fees$116,12593%
- Travel & lodging$6,5965%
- Food & beverage$2,0982%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 148 | $124,397 |
| Novo Nordisk | 7 | $126 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Lilly USA, LLC | 3 | $39 |
| Sequel Med Tech, LLC | 1 | $21 |
| Bayer | 1 | $19 |
| Novartis | 1 | $19 |
| Abbott | 1 | $17 |
| Amgen | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$122,830
How this compares
$124,825 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 293 | $254,716 |
| OzempicSemaglutide | 214 | $208,673 |
| MounjaroTirzepatide | 125 | $135,229 |
| Tresiba Flextouch U-100Insulin Degludec | 169 | $115,279 |
| Xigduo XrDapaglifloz Propaned/Metformin | 152 | $104,162 |
| Tresiba Flextouch U-200Insulin Degludec | 104 | $96,571 |
| TrulicityDulaglutide | 47 | $54,030 |
| Bydureon BciseExenatide Microspheres | 52 | $51,011 |
| RybelsusSemaglutide | 17 | $34,478 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $29,930 |
| EliquisApixaban | 16 | $12,047 |
| Repatha SureclickEvolocumab | 15 | $8,158 |
| Testosterone | 25 | $7,471 |
| JardianceEmpagliflozin | 13 | $7,373 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $7,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $124,397 | $254,716293 claims |
| Novo NordiskOzempic, Rybelsus | $126 | $243,150231 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $39 | $192,783189 claims |
| Boehringer IngelheimJardiance | $13 | $7,37313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Ada
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
- James BeebeMuskogee$66K
- Sarah HallTulsa$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.